MedTrace Logo

Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults

NCT04989972 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-30

No results posted yet for this study

Summary

To investigate the efficacy of a 16 week treatment with PSIL428 patient reported anxiety levels in otherwise healthy individuals suffering from depression and or anxiety symptoms.

Conditions

  • Anxiety and Depression

Interventions

DRUG

PSIL428

1 mg of psilocybin

DIETARY_SUPPLEMENT

Oyster mushroom

1 mg of oyster mushroom

DRUG

PSIL428

1 mg psilocybin

Sponsors & Collaborators

  • Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI

    collaborator UNKNOWN

  • Wake Network, Inc.

    lead NETWORK

Principal Investigators

  • Roger Gibson · Faculty of Medical Sciences UWI Mona

  • Sharon White · Wake Network, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-06-20
Completion
2023-08-31

Countries

  • Jamaica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989972 on ClinicalTrials.gov